Free Newsletter
Early trial backs use of artificial skin tissue
The UK's Intercytex has unveiled new early-stage data that supports its contention that an experimental artificial skin can reduce scarring. ICX-SKN is based on proteins found in wounds undergoing the healing process. Researchers have added fibroblasts to manufacture tissue that closely replicates the body's mechanism for developing new skin. The lab-made tissue was fully integrated in volunteers in 28 days. Squares of skin were cut from the bodies of six volunteers and replaced with the artificial tissue in the trial.
- read the Cosmetics Design report
Related Article:
Intercytex raises £12M in new venture round. Report
New type of cells developed for tissue repair. Report
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
SHARE
WITH: